A randomised controlled crossover pilot study of meropenem standard 30 minute infusion versus prolonged 3 hour infusion in intensive care patients

Phase 4

Completed

• Conditions: Sepsis; Infection - Studies of infection and infectious agents

• Registration Number: ACTRN12612000284864
• Lead Sponsor: Austin Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-03-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Adult intensive care patients
Sepsis
Predicted duration of treatment more than 3 days

Exclusion Criteria

Predicted duration of treatment < 3 days
Hypersensitivity to meropenem or other beta-lactams

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time above mean inhibitory concentration[During dosing interval (from start of infusion to prior to commencement of next infusion). Eight hours if creatinine clearance equal or greater than 50 mls/min and 12 hours if less than 50 mls/min]

Secondary Outcome Measures

Name	Time	Method
il[Nil]